Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The Wolf piezolith 2300: lights and shadows].

P Tombolini, M Ruoppolo, C Bellorofonte

    Archivio Italiano Di Urologia, Nefrologia, Andrologia : Organo Ufficiale Dell'Associazione Per La Ricerca in Urologia = Urological, Nephrological, and Andrological Sciences
    |December 1, 1989
    PubMed
    Summary

    The Piezolith 2300, a mobile extracorporeal piezoceramic lithotripter, offers a pain-free treatment for kidney and ureteral stones with a 90.2% disintegration success rate. This method avoids patient irradiation and requires minimal auxiliary support, establishing it as a primary choice for stone treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Metabolomic profiling of saliva from cystic fibrosis patients.

    Scientific reports·2025
    Same author

    A Phospholipid Profile at 4 Months Predicts the Onset of Celiac Disease in at-Risk Infants.

    Scientific reports·2019
    Same author

    Interactions between heme and tau-derived R1 peptides: binding and oxidative reactivity.

    Dalton transactions (Cambridge, England : 2003)·2016
    Same author

    Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.

    Journal of clinical pathology·2014
    Same author

    Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

    Clinical lymphoma, myeloma & leukemia·2014
    Same author

    Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer.

    Journal of clinical pathology·2014

    Area of Science:

    • Urology
    • Medical Engineering
    • Nephrology

    Background:

    • The Wolf Piezolith 2300 is an extracorporeal lithotripter developed in West Germany.
    • This mobile unit eliminates the need for water tubes, patient irradiation, special room adaptations, electrode replacement, or auxiliary staff.
    • It utilizes piezoceramic technology for stone disintegration.

    Purpose of the Study:

    • To evaluate the efficacy and safety of the Piezolith 2300 for treating reno-ureteral stones.
    • To assess the success rates and complication profile of this novel lithotripter.

    Main Methods:

    • A total of 230 stones in 218 patients (18-79 years old) were treated between February 1988 and May 1989.
    • Ultrasound localization was used, failing in 7 cases of ureteral stones.

    Related Experiment Videos

  • The mean number of sessions was 3000 (range 800-6500) per piezoelectric session; 12% of patients required 4 or more sessions.

    • Main Results:

    • Successful stone disintegration was achieved in 90.2% of cases (210 out of 230 stones).
    • Only 1.8% of patients required ancillary procedures post-treatment, with no major complications observed.
    • Stone-free rates were 57.3% at 30 days and 75% at 3 months.

    Conclusions:

    • Extracorporeal Piezoceramic Lithotripsy (EPL) with the Piezolith 2300 is a safe and effective treatment for reno-ureteral stones.
    • The procedure is largely painless, requiring minimal auxiliary measures.
    • EPL is considered a first-choice treatment option for approximately 70% of reno-ureteral stones.